Form 4: Jacob Ma-Weaver Reports Changes in Beneficial Ownership of ARCA biopharma, Inc. Following Business Combination

Jacob Ma-Weaver, formerly a director of ARCA biopharma, Inc., reports changes in beneficial ownership following the company's business combination on August 29, 2024, including the cancellation of incentive options and assignment of proceeds.

Summary

• Jacob Ma-Weaver filed a Form 4 to report changes in his beneficial ownership of ARCA biopharma, Inc. (ABIO) stock.
• The filing is triggered by the closing of ARCA biopharma's business combination on August 29, 2024.
• As a result of the business combination, Ma-Weaver is no longer a director of the Issuer and the group no longer holds more than 10% of its outstanding shares of Common Stock.
• Outstanding incentive options were canceled, and holders received cash based on the difference between $3.9489 and the option's exercise price.
• Ma-Weaver assigned the proceeds from the option cash-out to Funicular Funds, LP.
• The reported transactions involve stock options with exercise prices of $1.64, $2.32, and $2.27.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral.

Future Outlook

There is no future outlook provided in this document.

Industry Context

This Form 4 filing is a routine regulatory requirement following a significant corporate event like a business combination. It provides transparency into the ownership changes of key company stakeholders.

Stakeholder Impact

• Shareholders are informed about changes in ownership by a former director.
• The business combination impacts the ownership structure of the company.

Key Dates